

Diagnosis and management of
FETAL ANEMIA

(Essay)

**Submitted for Partial Fulfilment of Master Degree in
Obstetrics and Gynecology**

By

Zeinab Mehrize AL dosuky Hegazy

M. B., BCh, 1988

**Faculty of Medicine- Alazhar university
Medical sector of people assembly**

Supervised By

Prof. Dr. Ali Elyan Khalfallah

**Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University**

Prof. Dr. Hassan Tawfik Khairy

**Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University**

Dr.Ahmed Mohamed Ibrahim

**Lecturer in Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University**

(2005)

To the memory of
my father
and
my sister

Acknowledgment

First and foremost, thanks to God, the most beneficial and most merciful.

It is my pleasure to express my sincerest acknowledgment to **DR. ALY ELYAN KHALAF ALLAH**, professor of obstetrics and Gynecology, Faculty of Medicine, Ain-Shams University, for his generous support and valuable supervision which enriched the work by his great knowledge and experience.

I wish to express my deepest appreciation and gratefulness to **DR. HASSAN TAWFIK KHAIRY** Gynecology, Faculty of Medicine, Ain-Shams University, for his almost help, kind indispensable support, cooperation and continuous encouragement in performing this work.

I Also, owe a particular dept of gratitude to **DR. AHMED MOHAMED IBRAHIM**, lecturer in Obstetrics and Gynecology, Faculty of Medicine, Ain-Shams University, for his constructive guidance and general help in accomplishing this work.

Last but not least, I gratefully acknowledge the sincere help and support of my husband Refaat and my kids Ramy & Radwa for them patency all that time

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة الآية 32

DIAGNOSIS AND MANAGEMENT OF INTRAUTERINE FETAL ANEMIA

Essay

**Submitted for Partial Fulfilment of Master Degree in
Obstetrics and Gynecology**

**By
Zeinab Mehrize AL dosuky Hegazy
M. B., Bch, 1988**

Supervised By

Prof. Dr. Ali Elyan Khalfallah

**Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University**

Prof. Dr. Hassan Tawfik Khairy

**Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University**

Dr.Ahmed Mohamed Ibrahim

**Lecturer of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University**

(2004)

INTRODUCTION

Fetal anemia is defined as hematocrit or hemoglobin concentration $>2SD$ below the mean for gestational age. (Harrington and Fayyad 2002)

With the dawn of the new millennium, medical science has made little impact on the major complication of pregnancy. The one notable exception is rhesus alloimmunization and its associated fetal / neonatal consequence. (Lokeshwar et al 2003)

Antenatal serology screening and the widespread use of anti-D immunoglobulin has dramatically reduced the incidence of immune anemia. (Kumpel 2002)

Consequently, less common causes, such as parvovirus infection, are now becoming relatively more common causes of this serious condition.

Despite these developments, fetal anemia is an important cause of perinatal morbidity and mortality. The following facts remain true: fetal anemia can be caused by immune, non-immune and idiopathic causes and up to 50% of patients referred with red blood cell antibodies have those directed against an antigen other than D. (Lehmann et al 2003)

Etiological factors of fetal anemia can be caused by immune, non immune, and idiopathic causes. Among the immune causes, anti-D Rhesus antibodies are the most common. The administration of the anti-D Ig to all pregnant women at risk has dramatically decreased the incidence of Rh

-hemolytic disease . However,the use of anti -D has not eliminated the problem of alloimmunization ,since more than 50 Red blood cell irregular antigens will continue to be a problem .Currently, there are no routine method to measure the levels of non-D antibodies, and even the titres of these antibodies are not reliable predictor of the severity.In addition, immunoprophylaxis is not available to prevent these causes .(Moise 2002)

Non-immune causes of fetal anemia include hemolytic causes (alpha-thalassemia,red blood cells enzymes and membrane defects, microangiopathic and others), aplastic causes (parvovirus B-19 infection, other congenital infections,Diamond -Blackfan anemia, Fanconi s anemia and others) and hemorrhagic causes (FMH,FP twin-twin transfusion, chorioangioma, vasa previa and internal hemorrhage) . Again, no routine accurate screening test exists, and the diagnosis is often late when hydrops has occurred . Accordingly in spite of the modern advancement in materno-fetal medicine, fetal anemia remains an important cause of perinatal mortality and morbidity .(Leung etal 2002)

Diagnostic approaches : Initially, the diagnosis in case of Rh isoimmunization begins with past obstetric history and maternal antibody titre measurement . If the titre is negative ,it should be repeated monthly up till the time of delivery ,and the woman given anti-D Ig. On the other hand, once the critical level of antibody titre is exceeded, the patient should be regarded at risk and other forms of fetal evaluation are needed . The diagnosis of other causes of fetal anemia depends on the

underlying etiology e. g. fetal and maternal DNA samples are used to diagnosis alpha-thalassemia, and parvovirus infection is diagnosed by detection of its DNA in maternal or fetal tissues using the PCR technique .(Opkes 2000)

Noninvasive tests (ultrasound assessment and fetal Doppler measurement of fetal circulation) to predict fetal anemia are of value not only in avoiding unnecessary invasive procedures but also in deciding on the appropriate timing of intervention .(Roberts et al 2002)

Doppler blood velocity studies (especially fetal middle cerebral artery –of peak systolic velocity) appear to be the most valuable single noninvasive test .When sonographers are appropriately trained .(Zimmerman et al 2002)

Therapeutic Modalities : intrauterine transfusion is the most effective treatment in the management of most causes of fetal anemia . In cases of previous perinatal loss in the early second trimester Intravenous Immunoglobulin alone or in combination with plasmapheresis may enable the fetus to reach a gestation at which intravenous transfusion becomes feasible

Possible future advances in therapy include selective immunotherapy to block or suppress maternal anti-red cell antibodies .

(Marie et al 2004)

Aim of work : spots lights on these types of fetal anemia and trials of the intervention or prevention .

References

- (1) Harrington K and Fayyad A. Prediction of fetal anemia. Curr Opin in Obstet Gynecol. 2002;14:177- 185.
- (2) Kumpel B. Principles of antibody-mediated immune suppression and the prevention of maternal RhD alloimmunization. In Alloimmune disorders of pregnancy,Cambridge University Press. 2002; Chapter 5:73-96.
- (3) Lokeshwar Mr, Singhal T, and Shah N. Anemia in the newborn. India J Pediatr. 2003;70 (11):893-90
- (4) Leung WC, Oepkes D, Seaward G et al serial sonographic finding of four fetuses with homozygous alpha-thalassemia-1 from 21 weeks onwards. Ultrasound Obstet Gynecol. 2002;19:56-59.
- (5) Lehmann HW, Von Landenberg P ,Modrow S .Parvovirus B19 infection and autoimmune Rev. 2003;2:218-223.
- (6) Marie HP, Olivier P, Yves B et al. Intra venous exchange transfusion before 22 weeks of gestation in early and severe red cell fetomaternal alloimmunization. Obstet Gynecol. 2004;59(5):327-8.
- (7) Moise Jr Management of rhesus rhesus alloimmunization in pregnancy. Obstet Gynecol. 2002;100:600-11.
- (8) Oepkes D. Invasive versus non-invasive testing in red-cell alloimmunized pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000; 92:83-93.

- (9) Roberts AB , Mitchll JM , Lake Ypattison NS. Ultrasonographic surveillance in red blood cell alloimmunization. AMJ Obstet Gynecol .2002; 184:1251-1255.
- (10) Zimmerman R , Durig P , Carpenter RJ , etal. longitudinal mea surement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complication by red blood cell alloimmunization:a prospective multicentre trial with intention-to treat. Br J Obstet Gynecol.2002;109:746-752.

Index

Review of literature

Introduction	1
Aim of work	4
Chpater 1 - Embryological background	5
Developmental hematopoiesis occurs in three anatomic stages:	5
Erythropoiesis	6
Hemoglobin (Hb)	6
Changes in Hb and erythroid cells during pregnancy:	7
Fetal anemia (fa)	9
Classifications of fetal anemia	10
Chapter 2 - alloimmune fetal anemia	13
Blood group terminology	13
The genetics of blood groups	14
Identification of paternal zygosity	15
Identification of fetal blood type	15
Effects of Antigen Expression on Pathogenicity and Severity of HDFN	17
Antibodies cousing HDFN	18
Antibodies that most commonly cause 1 - moderate or severe HDFN	18
2 - Antibodies that most commonly cause mild HDFN (abo system)	22
Antibodies that rarely cause HDFN 3-	22
Antibodies that do not cause HDFN 4-	22
PATHOPHYSIOLOGY OF ALLOIMMUNE FETAL ANEMIA	23
Maternal exposure to the Antigens	23
Maternal immune Response:	24
Fetal Effects	25

Neonatal Effects	26
Prevention of RhD Immunization (Immunoprophylaxis)	27
Possible mechanisms of action	28
Doses and indications of immunoprophylaxis	29
I) Antenatal prophylaxis administration	29
II) Postpartum immunoprophylaxis administration	33
Risks of anti-D Ig immunoprophylaxis	36
Non-invasive diagnosis of Alloimmune Fetal Anemia	37
Past obstetric history	37
Maternal Antibody levels	38
Methods used in measuring maternal antibody levels	39
Other red cell antibodies	40
Ultrasound Findings	40
Fetal Hydrops	40
Fetal liver and spleen size	42
Fetal cardiac morphology	42
Fetal Heart rate Monitoring	43
Fetal Doppler Ultrasonography	43
Middle Cerebral Artery (MCA)	44
MCA-PSV as a predictor of FA and monitoring patients at risk	46
Effect of correction of fa on MCA-PSV	47
Use of MCA-PSV for timing the second transfusion	48
Fetal Aorta	48
Splenic Artery	49
Invasive Siagnosis of Fetal Anemia	49
Background	49
Amniocentesis	49
Fetal blood sampling	53
Technique blood sampling	54
Fetal blood indices	54
A- fetal hemoglobin and hematocrit	54
B- fetal blood reticulocyte, erthropoietin & erythoblast count	55
Fetal Bilirubin levels	55

Complications of the Invasive diagnosis of FA	55
Management of Allo Immune Fetal Anemia	56
i- Non-Invasive Treatment of Alloimmune Fetal Anemia	56
1 - plasmapheresis	56
2 - Intravenous immunoglobulin (ivig)	57
3 - Oral tolerance	58
4 - Chemotherapeutic agents	59
5 - Sensitization to paternal leukocyte antigens	59
ii- Intrauterine transfusion	60
Routes of intrauterine transfusion	60
Hematological criteria for intrauterine transfusion	61
Blood used during intrauterine transfusion	62
Amount of red cells transfusion	62
Time to repeat the transfusion	63
Timing of delivery	63
Complications of IVT	64
iii- Short-Term Outcome and Neonatal Management	64
iv- Long-Term Outcome	65
Chapter 3 - Nonimmune Hemolytic Fetal Anemia	66
i- Nonimmune hemolytic fetal anemia	66
Background	66
Classification non-immune fetal anemia	66
1 – Hemoglobinopathy	67
Alpha Thalassemias	69
Genetics and pathophysiology	70
Diagnosis	71
Treatment and Prognosis	71
Fetal Methemoglobinemia (HbM)	72
2 - Red-Cell Enzyme Defects (Enzymopathies)	72
(a) glucose-6-phosphate dehydrogenase deficiency (G-6PD)	72
(B) pyruvate kinase (PK) deficiency	73
(C) Glucose phosphate isomerase deficiency	74
3 - Red Cell Membrane Defects	74

4 - Microangiopathic Hemolytic Anemia	75
(a) Kasabach-Merritt Syndrome (KMS)	75
(B) Umbilical Vein Varix	75
(C) placental chorioangioma	75
(5) Iatrogenic Hemolytic Anemia	76
(6) Congenital Malaria	76
ii- Aplastic Fetal Anemia	77
1 - Parvovirus B19 Infection in Pregnancy	77
Clinical manifestations	77
Fetal infection	78
Diagnosis of parovirus B19	79
Management of parvovirus-B-19	80
2 - other congenital infections	80
3 - Congenital Hypoplastic Anemia [Diamond-Blackfan Anemia (DBA)]	81
4 - Fanconi's Anemia	82
5 - Other Causes Of Aplastic Fetal Anemia	82
iii- Hemorrhagic anemia of the fetus	83
(1) Fetomaternal Hemorrhage (FMH)	83
(2) Feto Placental Hemorrhage (FPH)	85
(3) Twin-Twin Transfusion	85
(4) Placental Chorioangioma	86
(5) Vasa Previa	88
(6) other causes of fetal hemorrhagic anemia	89
Chapter 4 - Neonatal anemia	90
Causes of neonatal anemia	90
Clinical Findings	93
Diagnostic evaluation of neonatal anemia	95
Management	96
Chapter 5 - Recommendation of Diagnosis and Management of fetal Anemia	98
i- for Rh Isoimmunization	98
For Non-D Isoimmunization (Other Causes)	99
Summary	100
References	103

Liste of table

Table (1) Reference ranges for fetal hemoglobin concentrations as a function of gestational age:	8
Table (2)Average hematological values in the fetus (Quoted from Lokeshwar et al, 2003)	9
Table (3) Some Red Cell Antigens and Their Propensity to Cause Hemolytic Disease in the Fetus-Infant Whose Mother is immunized	20
Table (4) Events following which anti-D Ig must be given to all Rh D-negative women with no RhD antibody and/or with antibodies other than anti-D	30
Table(5)Prophylactic anti-D Following abortions to all RhD negative women with no RhD antibody and/or with antibodies other than anti-D	31